Oscar Health (OSCR) Financials

$12.46 +0.05 (+0.36%)

Closing price 04/15/2025 03:59 PM Eastern

Extended Trading

$12.25 -0.22 (-1.72%)

As of 05:44 AM Eastern

Annual Income Statements for Oscar Health

This table shows Oscar Health's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-261	-407	-573	-606	-271	25
Consolidated Net Income / (Loss)	-261	-407	-571	-610	-271	26
Net Income / (Loss) Continuing Operations	-261	-407	-571	-610	-271	26
Total Pre-Tax Income	-259	-406	-571	-610	-267	33
Total Operating Income	-259	-402	-544	-590	-236	57
Total Gross Profit	80	153	215	683	5,863	9,178
Total Revenue	488	463	1,839	3,964	5,863	9,178
Operating Revenue	488	463	1,839	3,964	5,863	9,178
Total Cost of Revenue	408	309	1,624	3,281	0.00	0.00
Total Operating Expenses	339	556	759	1,273	6,098	9,120
Selling, General & Admin Expense	111	167	265	1,257	1,426	1,756
Depreciation Expense	-	-	-	15	31	32
Other Operating Expenses / (Income)	229	389	494	-	4,642	7,333
Total Other Income / (Expense), net	0.00	-3.51	-26	-20	-32	-24
Interest Expense	-	3.51	25	23	25	24
Other Income / (Expense), net	-	-	-1.20	2.42	-7.08	-0.11
Income Tax Expense	1.79	1.05	0.85	-0.52	3.29	7.31
Net Income / (Loss) Attributable to Noncontrolling Interest	0.00	0.00	1.18	-3.28	0.13	0.69
Basic Earnings per Share	($9.06)	($14.16)	($3.20)	($2.85)	($1.22)	$0.11
Weighted Average Basic Shares Outstanding	28.81M	29.26M	178.97M	212.48M	221.66M	240.39M
Diluted Earnings per Share	($9.06)	($14.16)	($3.20)	($2.85)	($1.22)	$0.10
Weighted Average Diluted Shares Outstanding	28.81M	29.26M	178.97M	212.48M	221.66M	265.85M
Weighted Average Basic & Diluted Shares Outstanding	-	-	210.40M	216.30M	229.73M	250.57M

This table shows Oscar Health's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-193	-226	-40	-16	-65	-150	177	56	-55	-154
Consolidated Net Income / (Loss)	-194	-227	-40	-15	-66	-150	177	56	-54	-153
Net Income / (Loss) Continuing Operations	-194	-227	-40	-15	-66	-150	177	56	-54	-153
Total Pre-Tax Income	-195	-227	-38	-14	-65	-151	178	61	-52	-154
Total Operating Income	-192	-222	-25	-6.53	-58	-145	186	68	-48	-148
Total Gross Profit	126	577	1,470	340	277	3,777	588	511	2,423	5,656
Total Revenue	978	995	1,470	1,522	1,440	1,432	2,142	2,219	2,423	2,392
Operating Revenue	978	995	1,470	1,522	1,440	1,432	2,142	2,219	2,423	2,392
Total Cost of Revenue	853	418	0.00	1,182	1,163	-2,345	1,555	1,709	0.00	-3,263
Total Operating Expenses	318	799	1,495	346	335	3,922	402	443	2,472	5,804
Selling, General & Admin Expense	79	1,023	399	337	326	364	394	435	460	466
Depreciation Expense	-	-	4.94	8.82	9.19	7.74	7.81	7.60	7.50	9.23
Total Other Income / (Expense), net	-2.79	-4.80	-12	-7.73	-6.54	-5.17	-7.08	-6.86	-3.94	-5.96
Interest Expense	6.13	6.14	6.14	6.12	6.13	6.22	5.90	5.99	5.82	6.03
Other Income / (Expense), net	3.34	1.34	-6.11	-1.61	-0.41	1.05	-1.18	-0.87	1.88	0.07
Income Tax Expense	-1.62	-0.72	2.02	1.16	0.92	-0.81	1.00	4.64	2.08	-0.40
Net Income / (Loss) Attributable to Noncontrolling Interest	-0.63	-0.51	0.14	0.10	-0.31	0.19	0.11	0.11	0.21	0.26
Basic Earnings per Share	($0.91)	($1.05)	($0.18)	($0.07)	($0.29)	($0.68)	$0.77	$0.24	($0.22)	($0.68)
Weighted Average Basic Shares Outstanding	212.82M	212.48M	216.91M	219.40M	223.10M	221.66M	231.44M	238.67M	243.11M	240.39M
Diluted Earnings per Share	($0.91)	($1.05)	($0.18)	($0.07)	($0.29)	($0.68)	$0.62	$0.20	($0.22)	($0.50)
Weighted Average Diluted Shares Outstanding	212.82M	212.48M	216.91M	219.40M	223.10M	221.66M	293.80M	303.97M	243.11M	265.85M
Weighted Average Basic & Diluted Shares Outstanding	214.76M	216.30M	218.35M	221.91M	226.11M	229.73M	237.22M	241.91M	247.27M	250.57M

This table details how cash moves in and out of Oscar Health's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	-17	490	282	455	311	-341
Net Cash From Operating Activities	-165	223	-182	380	-272	978
Net Cash From Continuing Operating Activities	-165	223	-182	380	-272	978
Net Income / (Loss) Continuing Operations	-261	-407	-571	-610	-271	26
Consolidated Net Income / (Loss)	-261	-407	-571	-610	-271	26
Depreciation Expense	6.90	11	15	15	31	32
Amortization Expense	-6.65	2.92	8.36	3.19	-29	-26
Non-Cash Adjustments To Reconcile Net Income	79	382	78	490	-14	416
Changes in Operating Assets and Liabilities, net	17	233	289	482	10	530
Net Cash From Investing Activities	151	-345	-775	-227	577	-1,387
Net Cash From Continuing Investing Activities	151	-345	-775	-227	577	-1,387
Purchase of Property, Plant & Equipment	-26	-14	-26	-29	-26	-28
Purchase of Investments	-878	-1,001	-1,810	-1,193	-837	-2,134
Sale and/or Maturity of Investments	1,061	672	1,055	994	1,442	770
Other Investing Activities, net	-7.08	-1.24	6.68	1.12	-2.28	3.93
Net Cash From Financing Activities	-2.12	612	1,239	301	6.45	68
Net Cash From Continuing Financing Activities	-2.12	612	1,239	301	6.45	68
Repayment of Debt	0.00	-4.84	-166	-7.04	0.00	0.00
Issuance of Debt	-	147	0.00	305	0.00	0.00
Issuance of Common Equity	0.00	0.00	1,356	1.85	2.49	0.00
Other Financing Activities, net	0.87	94	59	1.30	3.96	68
Cash Interest Paid	0.00	0.00	4.26	10	23	34
Cash Income Taxes Paid	1.83	1.53	0.70	1.89	2.41	0.67

This table details how cash moves in and out of Oscar Health's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	-249	-555	551	212	-922	470	361	38	-1,059	319
Net Cash From Operating Activities	-548	151	415	166	-1,149	297	634	497	-500	347
Net Cash From Continuing Operating Activities	-548	151	415	166	-1,149	297	634	497	-500	347
Net Income / (Loss) Continuing Operations	-194	-227	-40	-15	-66	-150	177	56	-54	-153
Consolidated Net Income / (Loss)	-194	-227	-40	-15	-66	-150	177	56	-54	-153
Depreciation Expense	4.06	3.74	4.94	8.82	9.19	7.74	7.81	7.60	7.50	9.23
Amortization Expense	1.19	-1.46	-7.13	-7.76	-7.39	-6.32	-6.03	-5.80	-6.54	-7.73
Non-Cash Adjustments To Reconcile Net Income	-505	378	444	311	-1,140	370	151	399	-596	463
Changes in Operating Assets and Liabilities, net	145	-2.32	12	-131	54	75	304	40	149	36
Net Cash From Investing Activities	299	-707	136	44	225	172	-301	-478	-578	-31
Net Cash From Continuing Investing Activities	299	-707	136	44	225	172	-301	-478	-578	-31
Purchase of Property, Plant & Equipment	-9.62	-7.13	-7.38	-5.62	-6.48	-6.10	-5.95	-7.56	-7.57	-6.82
Purchase of Investments	-31	-850	-203	-335	-84	-215	-557	-806	-660	-110
Sale and/or Maturity of Investments	339	150	346	385	316	396	261	335	87	86
Other Investing Activities, net	0.53	-0.43	0.00	-0.52	0.62	-2.38	0.63	0.83	2.49	-0.01
Net Cash From Financing Activities	0.42	0.53	0.51	2.55	2.32	1.07	27	19	19	3.82
Net Cash From Continuing Financing Activities	0.42	0.53	0.51	2.55	2.32	1.07	27	19	19	3.82
Other Financing Activities, net	0.37	0.01	0.04	2.55	0.30	1.07	27	19	19	3.82
Cash Interest Paid	0.26	0.27	11	11	0.26	0.26	11	0.15	11	11
Cash Income Taxes Paid	0.56	0.23	-	-	0.60	1.41	-	-	0.55	0.04

This table presents Oscar Health's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024
Total Assets	2,272	3,322	4,527	3,601	4,840
Total Current Assets	1,870	2,306	4,122	3,061	2,845
Cash & Equivalents	826	1,104	1,559	1,870	1,527
Short-Term Investments	368	587	1,397	690	624
Accounts Receivable	65	138	216	201	316
Other Current Assets	611	476	949	300	378
Plant, Property, & Equipment, net	36	47	60	62	67
Total Noncurrent Assets	366	969	345	478	1,929
Long-Term Investments	352	873	250	395	1,846
Other Noncurrent Operating Assets	13	97	95	83	82
Total Liabilities & Shareholders' Equity	2,272	3,322	4,527	3,601	4,840
Total Liabilities	1,823	1,929	3,634	2,795	3,824
Total Current Liabilities	1,666	1,852	3,264	2,429	3,463
Accounts Payable	138	235	298	273	432
Other Current Liabilities	1,528	1,618	2,966	2,156	3,031
Total Noncurrent Liabilities	157	77	370	366	361
Long-Term Debt	142	0.00	298	299	300
Other Noncurrent Operating Liabilities	15	77	72	68	61
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-1,296	1,393	892	806	1,016
Total Preferred & Common Equity	-1,296	1,387	890	804	1,014
Total Common Equity	-1,296	1,387	890	804	1,014
Common Stock	133	3,394	3,509	3,682	3,870
Retained Earnings	-1,427	-2,000	-2,606	-2,877	-2,851
Treasury Stock	-2.92	-2.92	-2.92	-2.92	-2.92
Accumulated Other Comprehensive Income / (Loss)	0.88	-3.67	-9.72	1.31	-1.83
Noncontrolling Interest	0.00	5.29	2.02	2.15	2.84

This table presents Oscar Health's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	4,309	4,483	4,565	3,350	4,419	5,006	4,483
Total Current Assets	3,931	4,131	4,193	2,992	3,504	3,359	2,368
Cash & Equivalents	2,113	2,110	2,322	1,400	2,231	2,268	1,206
Short-Term Investments	718	1,325	1,256	1,044	616	364	504
Accounts Receivable	215	186	193	207	343	398	301
Other Current Assets	885	511	422	340	314	329	357
Plant, Property, & Equipment, net	56	64	63	62	61	64	67
Total Noncurrent Assets	321	288	309	296	854	1,583	2,048
Long-Term Investments	224	193	217	207	766	1,496	1,964
Other Noncurrent Operating Assets	97	95	92	89	87	87	84
Total Liabilities & Shareholders' Equity	4,309	4,483	4,565	3,350	4,419	5,006	4,483
Total Liabilities	3,224	3,551	3,613	2,428	3,385	3,866	3,318
Total Current Liabilities	2,853	3,182	3,244	2,061	3,019	3,502	2,955
Accounts Payable	252	299	262	260	303	348	395
Other Current Liabilities	2,600	2,882	2,983	1,801	2,716	3,154	2,559
Total Noncurrent Liabilities	372	370	369	367	365	364	363
Long-Term Debt	298	298	298	299	299	299	299
Other Noncurrent Operating Liabilities	74	71	70	69	66	65	64
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,085	932	952	921	1,034	1,141	1,165
Total Preferred & Common Equity	1,082	930	950	919	1,032	1,138	1,163
Total Common Equity	1,082	930	950	919	1,032	1,138	1,163
Common Stock	3,479	3,583	3,621	3,654	3,737	3,787	3,837
Retained Earnings	-2,380	-2,646	-2,661	-2,727	-2,699	-2,643	-2,698
Treasury Stock	-2.92	-2.92	-2.92	-2.92	-2.92	-2.92	-2.92
Accumulated Other Comprehensive Income / (Loss)	-14	-4.48	-6.86	-4.45	-2.59	-2.63	26
Noncontrolling Interest	2.53	2.16	2.26	1.96	2.26	2.37	2.58

This table displays calculated financial ratios and metrics derived from Oscar Health's official financial filings.

Metric	2019	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-	-
Revenue Growth	0.00%	-5.20%	297.30%	115.57%	47.92%	56.54%
EBITDA Growth	0.00%	-49.75%	-34.70%	-8.85%	57.71%	126.27%
EBIT Growth	0.00%	-55.08%	-35.65%	-7.65%	58.69%	123.55%
NOPAT Growth	0.00%	-55.08%	-35.35%	-8.34%	60.06%	127.13%
Net Income Growth	0.00%	-55.76%	-40.46%	-6.67%	55.61%	109.65%
EPS Growth	0.00%	-56.29%	77.40%	10.94%	57.19%	108.20%
Operating Cash Flow Growth	0.00%	234.69%	-181.60%	309.28%	-171.56%	459.42%
Free Cash Flow Firm Growth	0.00%	0.00%	-124.54%	361.25%	-176.50%	365.18%
Invested Capital Growth	0.00%	0.00%	-22.59%	-72.13%	8.21%	-44.93%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	14.40%	8.04%	11.69%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	-5.19%	23.97%	-4.74%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	-4.22%	24.02%	-5.36%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	-4.65%	24.63%	-7.26%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	-4.96%	22.09%	-11.66%
EPS Q/Q Growth	0.00%	0.00%	0.00%	-8.37%	23.27%	225.00%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	-42.84%	44.38%	34.83%	5.38%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	28.23%	6.03%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	-20.52%	-29.29%	-21.39%
Profitability Metrics	-	-	-	-	-	-
Gross Margin	16.37%	33.16%	11.68%	17.23%	100.00%	100.00%
EBITDA Margin	-53.08%	-83.85%	-28.43%	-14.35%	-4.10%	0.69%
Operating Margin	-53.13%	-86.92%	-29.61%	-14.88%	-4.02%	0.62%
EBIT Margin	-53.13%	-86.92%	-29.68%	-14.82%	-4.14%	0.62%
Profit (Net Income) Margin	-53.50%	-87.91%	-31.08%	-15.38%	-4.62%	0.28%
Tax Burden Percent	100.69%	100.26%	100.15%	99.91%	101.23%	78.15%
Interest Burden Percent	100.00%	100.87%	104.56%	103.85%	110.14%	58.48%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	21.85%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	0.00%	-90.60%	-62.06%	-53.35%	-31.86%	2.87%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	-17.70%	-19.51%	-14.97%	-5.97%	1.35%
Return on Assets (ROA)	0.00%	-17.91%	-20.43%	-15.53%	-6.66%	0.62%
Return on Common Equity (ROCE)	0.00%	261.49%	-3.08%	-53.18%	-31.78%	2.86%
Return on Equity Simple (ROE_SIMPLE)	0.00%	31.39%	-41.19%	-68.46%	-33.66%	2.58%
Net Operating Profit after Tax (NOPAT)	-182	-282	-381	-413	-165	45
NOPAT Margin	-37.19%	-60.84%	-20.73%	-10.42%	-2.81%	0.49%
Net Nonoperating Expense Percent (NNEP)	0.00%	-17.84%	-9.59%	-7.19%	-3.80%	-0.59%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-34.69%	-14.93%	3.40%
Cost of Revenue to Revenue	83.63%	66.84%	88.32%	82.77%	0.00%	0.00%
SG&A Expenses to Revenue	22.67%	36.01%	14.42%	31.72%	24.32%	19.13%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	69.51%	120.08%	41.29%	32.11%	104.02%	99.38%
Earnings before Interest and Taxes (EBIT)	-259	-402	-546	-587	-243	57
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-259	-388	-523	-569	-241	63
Valuation Ratios	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	1.19	0.59	2.57	3.28
Price to Tangible Book Value (P/TBV)	0.00	0.00	1.19	0.59	2.57	3.28
Price to Revenue (P/Rev)	2.96	3.12	0.89	0.13	0.35	0.36
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	130.67
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.77%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	3.86	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	8.02	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	2.65	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-
Debt to Equity	0.00	0.32	0.00	0.33	0.37	0.29
Long-Term Debt to Equity	0.00	0.32	0.00	0.33	0.37	0.29
Financial Leverage	0.00	-3.13	-2.15	-2.39	-3.28	-3.49
Leverage Ratio	0.00	5.06	3.04	3.43	4.79	4.63
Compound Leverage Factor	0.00	5.10	3.18	3.57	5.27	2.71
Debt to Total Capital	0.00%	24.09%	0.00%	25.03%	27.04%	22.76%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	24.09%	0.00%	25.03%	27.04%	22.76%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	295.00%	0.38%	0.17%	0.19%	0.22%
Common Equity to Total Capital	0.00%	-219.08%	99.62%	74.80%	72.76%	77.02%
Debt to EBITDA	0.00	-0.37	0.00	-0.52	-1.24	4.74
Net Debt to EBITDA	0.00	3.62	0.00	5.11	11.04	-58.51
Long-Term Debt to EBITDA	0.00	-0.37	0.00	-0.52	-1.24	4.74
Debt to NOPAT	0.00	-0.51	0.00	-0.72	-1.81	6.69
Net Debt to NOPAT	0.00	4.99	0.00	7.04	16.11	-82.64
Long-Term Debt to NOPAT	0.00	-0.51	0.00	-0.72	-1.81	6.69
Altman Z-Score	0.00	-0.68	-0.16	-0.04	0.94	1.48
Noncontrolling Interest Sharing Ratio	0.00%	388.61%	95.04%	0.32%	0.25%	0.27%
Liquidity Ratios	-	-	-	-	-	-
Current Ratio	0.00	1.12	1.24	1.26	1.26	0.82
Quick Ratio	0.00	0.76	0.99	0.97	1.14	0.71
Cash Flow Metrics	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	674	-165	432	-330	876
Operating Cash Flow to CapEx	-636.14%	1,588.56%	-702.12%	1,311.01%	-1,064.08%	3,506.45%
Free Cash Flow to Firm to Interest Expense	0.00	191.72	-6.64	19.09	-13.43	36.91
Operating Cash Flow to Interest Expense	0.00	63.38	-7.30	16.81	-11.06	41.21
Operating Cash Flow Less CapEx to Interest Expense	0.00	59.39	-8.34	15.53	-12.10	40.04
Efficiency Ratios	-	-	-	-	-	-
Asset Turnover	0.00	0.20	0.66	1.01	1.44	2.17
Accounts Receivable Turnover	0.00	7.08	18.05	22.34	28.07	35.49
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	12.92	44.62	74.44	96.26	142.59
Accounts Payable Turnover	0.00	2.25	8.72	12.32	0.00	0.00
Days Sales Outstanding (DSO)	0.00	51.52	20.22	16.34	13.00	10.28
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	162.26	41.84	29.63	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	-110.74	-21.62	-13.29	13.00	10.28
Capital & Investment Metrics	-	-	-	-	-	-
Invested Capital	0.00	-955	-1,171	-2,016	-1,850	-2,682
Invested Capital Turnover	0.00	-0.97	-1.73	-2.49	-3.03	-4.05
Increase / (Decrease) in Invested Capital	0.00	-955	-216	-845	165	-831
Enterprise Value (EV)	0.00	1,785	-914	-2,378	-585	-372
Market Capitalization	1,445	1,445	1,645	528	2,069	3,323
Book Value per Share	$0.00	($44.28)	$6.62	$4.15	$3.56	$4.10
Tangible Book Value per Share	$0.00	($44.28)	$6.62	$4.15	$3.56	$4.10
Total Capital	0.00	592	1,393	1,190	1,105	1,316
Total Debt	0.00	142	0.00	298	299	300
Total Long-Term Debt	0.00	142	0.00	298	299	300
Net Debt	0.00	-1,404	-2,564	-2,908	-2,657	-3,698
Capital Expenditures (CapEx)	26	14	26	29	26	28
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	-990	-1,237	-2,098	-1,928	-2,770
Debt-free Net Working Capital (DFNWC)	0.00	205	454	858	632	-618
Net Working Capital (NWC)	0.00	205	454	858	632	-618
Net Nonoperating Expense (NNE)	80	125	190	197	106	19
Net Nonoperating Obligations (NNO)	0.00	-1,404	-2,564	-2,908	-2,657	-3,698
Total Depreciation and Amortization (D&A)	0.25	14	23	18	2.10	6.05
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	-213.86%	-67.30%	-52.94%	-32.89%	-30.18%
Debt-free Net Working Capital to Revenue	0.00%	44.26%	24.67%	21.64%	10.78%	-6.73%
Net Working Capital to Revenue	0.00%	44.26%	24.67%	21.64%	10.78%	-6.73%
Earnings Adjustments	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	($3.20)	($2.85)	($1.22)	$0.11
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	178.97M	212.47M	221.66M	240.39M
Adjusted Diluted Earnings per Share	$0.00	$0.00	($3.20)	($2.85)	($1.22)	$0.10
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	178.97M	212.47M	221.66M	265.85M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	210.40M	216.30M	229.73M	250.57M
Normalized Net Operating Profit after Tax (NOPAT)	-182	-282	-381	-413	-165	45
Normalized NOPAT Margin	-37.19%	-60.84%	-20.73%	-10.42%	-2.81%	0.49%
Pre Tax Income Margin	-53.13%	-87.68%	-31.03%	-15.39%	-4.56%	0.36%
Debt Service Ratios	-	-	-	-	-	-
EBIT to Interest Expense	0.00	-114.48	-21.92	-25.97	-9.86	2.41
NOPAT to Interest Expense	0.00	-80.13	-15.31	-18.25	-6.70	1.89
EBIT Less CapEx to Interest Expense	0.00	-118.47	-22.96	-27.25	-10.90	1.23
NOPAT Less CapEx to Interest Expense	0.00	-84.12	-16.35	-19.53	-7.74	0.71
Payout Ratios	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-1.15%	0.00%	-1.65%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Oscar Health's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	120.38%	100.60%	51.08%	49.56%	47.17%	43.87%	45.77%	45.86%	68.30%	67.11%
EBITDA Growth	10.60%	-15.35%	48.79%	92.96%	69.07%	34.66%	653.06%	1,071.36%	19.90%	-2.20%
EBIT Growth	10.70%	-12.68%	56.04%	92.30%	68.97%	34.69%	685.87%	922.26%	20.73%	-2.24%
NOPAT Growth	9.12%	-13.36%	62.99%	93.87%	69.72%	34.61%	1,139.24%	1,470.87%	16.95%	-1.55%
Net Income Growth	8.48%	-14.57%	48.75%	86.24%	66.05%	33.86%	547.87%	465.07%	17.22%	-2.30%
EPS Growth	10.78%	-26.51%	50.00%	86.79%	68.13%	35.24%	444.44%	385.71%	24.14%	26.47%
Operating Cash Flow Growth	6.94%	339.09%	-26.32%	-22.82%	-109.58%	96.09%	52.96%	200.35%	56.48%	16.83%
Free Cash Flow Firm Growth	550.72%	0.00%	74.80%	-76.31%	-150.54%	-138.79%	-88.69%	-56.33%	363.62%	372.35%
Invested Capital Growth	-70.76%	-72.13%	-34.80%	-23.06%	14.44%	8.21%	4.86%	-5.64%	-54.36%	-44.93%
Revenue Q/Q Growth	-3.82%	1.71%	47.69%	3.53%	-5.36%	-0.58%	49.64%	3.60%	9.20%	-1.28%
EBITDA Q/Q Growth	-82.71%	-19.09%	84.62%	78.98%	-703.36%	-151.54%	230.17%	-63.07%	-166.25%	-220.94%
EBIT Q/Q Growth	-78.85%	-16.98%	85.77%	74.13%	-620.53%	-146.22%	227.66%	-63.69%	-169.46%	-217.58%
NOPAT Q/Q Growth	-80.65%	-15.65%	88.60%	74.26%	-792.08%	-149.77%	281.20%	-66.05%	-154.05%	-205.39%
Net Income Q/Q Growth	-72.62%	-17.06%	82.51%	61.08%	-325.95%	-128.05%	218.45%	-68.27%	-196.58%	-181.84%
EPS Q/Q Growth	-71.70%	-15.38%	82.86%	61.11%	-314.29%	-134.48%	191.18%	-67.74%	-210.00%	-127.27%
Operating Cash Flow Q/Q Growth	-355.69%	127.61%	173.93%	-60.09%	-794.32%	125.83%	113.69%	-21.63%	-200.60%	169.34%
Free Cash Flow Firm Q/Q Growth	-71.98%	23.38%	-12.78%	-21.43%	-159.79%	5.31%	125.42%	203.45%	260.90%	-2.18%
Invested Capital Q/Q Growth	19.10%	-20.52%	-18.89%	-6.16%	43.75%	-29.29%	-23.22%	-17.88%	17.81%	-21.39%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	12.85%	57.95%	100.00%	22.32%	19.22%	263.81%	27.43%	23.01%	100.00%	236.41%
EBITDA Margin	-18.78%	-21.99%	-2.29%	-0.47%	-3.95%	-9.99%	8.69%	3.10%	-1.88%	-6.11%
Operating Margin	-19.66%	-22.36%	-1.73%	-0.43%	-4.04%	-10.16%	8.66%	3.06%	-2.00%	-6.17%
EBIT Margin	-19.32%	-22.22%	-2.14%	-0.54%	-4.07%	-10.09%	8.61%	3.02%	-1.92%	-6.17%
Profit (Net Income) Margin	-19.78%	-22.77%	-2.70%	-1.01%	-4.56%	-10.47%	8.28%	2.54%	-2.24%	-6.41%
Tax Burden Percent	99.17%	99.69%	105.37%	108.16%	101.41%	99.47%	99.44%	92.39%	103.97%	99.74%
Interest Burden Percent	103.24%	102.77%	119.50%	175.18%	110.45%	104.30%	96.80%	91.05%	112.51%	104.08%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.56%	7.61%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-44.03%	-53.35%	-50.45%	-43.19%	-34.63%	-31.86%	-5.44%	1.74%	2.83%	2.87%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-17.90%	-22.45%	-2.16%	-0.57%	-5.77%	-14.55%	12.64%	4.56%	-4.03%	-13.42%
Return on Assets (ROA)	-18.33%	-23.00%	-2.72%	-1.08%	-6.47%	-15.10%	12.16%	3.84%	-4.71%	-13.93%
Return on Common Equity (ROCE)	-43.99%	-53.18%	-50.33%	-43.08%	-34.55%	-31.78%	-5.43%	1.74%	2.83%	2.86%
Return on Equity Simple (ROE_SIMPLE)	-53.67%	0.00%	-61.52%	-50.03%	-37.77%	0.00%	-5.18%	1.60%	2.54%	0.00%
Net Operating Profit after Tax (NOPAT)	-135	-156	-18	-4.57	-41	-102	185	63	-34	-103
NOPAT Margin	-13.76%	-15.65%	-1.21%	-0.30%	-2.83%	-7.11%	8.61%	2.82%	-1.40%	-4.32%
Net Nonoperating Expense Percent (NNEP)	-2.23%	-2.59%	-0.68%	-0.32%	-0.98%	-1.73%	-0.21%	-0.17%	-0.72%	-1.57%
Return On Investment Capital (ROIC_SIMPLE)	-	-13.08%	-	-	-	-9.22%	-	-	-	-7.86%
Cost of Revenue to Revenue	87.15%	42.05%	0.00%	77.68%	80.78%	-163.81%	72.57%	76.99%	0.00%	-136.41%
SG&A Expenses to Revenue	8.03%	102.85%	27.12%	22.16%	22.63%	25.44%	18.40%	19.61%	19.00%	19.47%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	32.51%	80.31%	101.73%	22.74%	23.27%	273.97%	18.76%	19.95%	102.00%	242.58%
Earnings before Interest and Taxes (EBIT)	-189	-221	-31	-8.14	-59	-144	184	67	-46	-148
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-184	-219	-34	-7.08	-57	-143	186	69	-46	-146
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.98	0.59	1.52	1.85	1.34	2.57	3.26	3.30	4.41	3.28
Price to Tangible Book Value (P/TBV)	0.98	0.59	1.52	1.85	1.34	2.57	3.26	3.30	4.41	3.28
Price to Revenue (P/Rev)	0.31	0.13	0.32	0.35	0.23	0.35	0.51	0.52	0.62	0.36
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	206.80	177.24	130.67
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.48%	0.56%	0.77%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.00	0.21	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	26.51	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	29.12	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	36.45	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.89	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.13	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.27	0.33	0.32	0.31	0.32	0.37	0.29	0.26	0.26	0.29
Long-Term Debt to Equity	0.27	0.33	0.32	0.31	0.32	0.37	0.29	0.26	0.26	0.29
Financial Leverage	-2.01	-2.39	-2.84	-3.10	-2.55	-3.28	-3.38	-3.50	-2.74	-3.49
Leverage Ratio	2.84	3.43	3.90	4.23	3.82	4.79	4.53	4.57	3.75	4.63
Compound Leverage Factor	2.93	3.53	4.66	7.42	4.22	4.99	4.38	4.16	4.22	4.82
Debt to Total Capital	21.54%	25.03%	24.24%	23.86%	24.47%	27.04%	22.42%	20.78%	20.44%	22.76%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	21.54%	25.03%	24.24%	23.86%	24.47%	27.04%	22.42%	20.78%	20.44%	22.76%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.18%	0.17%	0.18%	0.18%	0.16%	0.19%	0.17%	0.16%	0.18%	0.22%
Common Equity to Total Capital	78.27%	74.80%	75.58%	75.95%	75.37%	72.76%	77.41%	79.06%	79.39%	77.02%
Debt to EBITDA	-0.55	-0.52	-0.56	-0.67	-0.94	-1.24	-14.39	5.44	4.51	4.74
Net Debt to EBITDA	5.10	5.11	6.20	7.89	7.43	11.04	159.50	-69.56	-50.86	-58.51
Long-Term Debt to EBITDA	-0.55	-0.52	-0.56	-0.67	-0.94	-1.24	-14.39	5.44	4.51	4.74
Debt to NOPAT	-0.75	-0.72	-0.78	-0.95	-1.36	-1.81	-17.30	7.92	6.20	6.69
Net Debt to NOPAT	6.99	7.04	8.70	11.18	10.75	16.11	191.76	-101.37	-69.93	-82.64
Long-Term Debt to NOPAT	-0.75	-0.72	-0.78	-0.95	-1.36	-1.81	-17.30	7.92	6.20	6.69
Altman Z-Score	0.38	0.22	0.64	0.81	1.06	1.03	1.49	1.30	1.73	1.34
Noncontrolling Interest Sharing Ratio	0.10%	0.32%	0.23%	0.25%	0.22%	0.25%	0.23%	0.22%	0.22%	0.27%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.38	1.26	1.30	1.29	1.45	1.26	1.16	0.96	0.80	0.82
Quick Ratio	1.07	0.97	1.14	1.16	1.29	1.14	1.06	0.87	0.68	0.71
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	558	689	601	472	-282	-267	68	206	744	728
Operating Cash Flow to CapEx	-5,702.00%	2,123.34%	5,620.21%	2,946.84%	-17,738.32%	4,865.09%	10,661.56%	6,574.33%	-6,610.38%	5,086.08%
Free Cash Flow to Firm to Interest Expense	91.17	112.31	97.94	77.15	-46.05	-42.99	11.51	34.42	127.97	120.80
Operating Cash Flow to Interest Expense	-89.51	24.68	67.59	27.05	-187.48	47.75	107.48	82.98	-86.01	57.55
Operating Cash Flow Less CapEx to Interest Expense	-91.08	23.51	66.38	26.13	-188.54	46.77	106.47	81.72	-87.31	56.42
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.93	1.01	1.01	1.07	1.42	1.44	1.47	1.51	2.10	2.17
Accounts Receivable Turnover	20.81	22.34	25.98	27.03	25.68	28.07	24.71	24.46	32.37	35.49
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	69.38	74.44	79.17	87.11	91.57	96.26	104.16	113.90	127.74	142.59
Accounts Payable Turnover	15.76	12.32	8.90	10.06	10.79	0.00	20.56	22.08	16.96	0.00
Days Sales Outstanding (DSO)	17.54	16.34	14.05	13.50	14.21	13.00	14.77	14.92	11.28	10.28
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	23.15	29.63	41.01	36.29	33.84	0.00	17.75	16.53	21.52	0.00
Cash Conversion Cycle (CCC)	-5.61	-13.29	-26.96	-22.79	-19.63	13.00	-2.98	-1.61	-10.24	10.28
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-1,673	-2,016	-2,397	-2,544	-1,431	-1,850	-2,280	-2,688	-2,209	-2,682
Invested Capital Turnover	-2.61	-2.49	-2.14	-2.15	-3.50	-3.03	-2.79	-2.76	-4.51	-4.05
Increase / (Decrease) in Invested Capital	-693	-845	-619	-477	242	165	117	-144	-778	-831
Enterprise Value (EV)	-1,696	-2,378	-1,912	-1,734	-1,115	-585	50	-73	1,759	-372
Market Capitalization	1,059	528	1,415	1,760	1,236	2,069	3,362	3,753	5,131	3,323
Book Value per Share	$5.10	$4.15	$4.30	$4.35	$4.14	$3.56	$4.46	$4.80	$4.81	$4.10
Tangible Book Value per Share	$5.10	$4.15	$4.30	$4.35	$4.14	$3.56	$4.46	$4.80	$4.81	$4.10
Total Capital	1,382	1,190	1,230	1,250	1,220	1,105	1,333	1,440	1,465	1,316
Total Debt	298	298	298	298	299	299	299	299	299	300
Total Long-Term Debt	298	298	298	298	299	299	299	299	299	300
Net Debt	-2,757	-2,908	-3,328	-3,496	-2,353	-2,657	-3,314	-3,828	-3,375	-3,698
Capital Expenditures (CapEx)	9.62	7.13	7.38	5.62	6.48	6.10	5.95	7.56	7.57	6.82
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-1,753	-2,098	-2,485	-2,629	-1,513	-1,928	-2,363	-2,774	-2,297	-2,770
Debt-free Net Working Capital (DFNWC)	1,079	858	950	948	931	632	484	-143	-587	-618
Net Working Capital (NWC)	1,079	858	950	948	931	632	484	-143	-587	-618
Net Nonoperating Expense (NNE)	59	71	22	11	25	48	7.04	6.34	21	50
Net Nonoperating Obligations (NNO)	-2,757	-2,908	-3,328	-3,496	-2,353	-2,657	-3,314	-3,828	-3,375	-3,698
Total Depreciation and Amortization (D&A)	5.25	2.27	-2.19	1.06	1.80	1.42	1.78	1.80	0.96	1.51
Debt-free, Cash-free Net Working Capital to Revenue	-50.58%	-52.94%	-55.70%	-52.96%	-27.89%	-32.89%	-36.15%	-38.36%	-27.95%	-30.18%
Debt-free Net Working Capital to Revenue	31.13%	21.64%	21.29%	19.10%	17.15%	10.78%	7.41%	-1.97%	-7.14%	-6.73%
Net Working Capital to Revenue	31.13%	21.64%	21.29%	19.10%	17.15%	10.78%	7.41%	-1.97%	-7.14%	-6.73%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.91)	($1.05)	($0.18)	($0.07)	($0.29)	($0.68)	$0.77	$0.24	($0.22)	($0.68)
Adjusted Weighted Average Basic Shares Outstanding	212.82M	212.48M	216.91M	219.40M	223.10M	221.66M	231.44M	238.67M	243.11M	240.39M
Adjusted Diluted Earnings per Share	($0.91)	($1.05)	($0.18)	($0.07)	($0.29)	($0.68)	$0.62	$0.20	($0.22)	($0.50)
Adjusted Weighted Average Diluted Shares Outstanding	212.82M	212.48M	216.91M	219.40M	223.10M	221.66M	293.80M	303.97M	243.11M	265.85M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	214.76M	216.30M	218.35M	221.91M	226.11M	229.73M	237.22M	241.91M	247.27M	250.57M
Normalized Net Operating Profit after Tax (NOPAT)	-135	-156	-18	-4.57	-41	-102	185	63	-34	-103
Normalized NOPAT Margin	-13.76%	-15.65%	-1.21%	-0.30%	-2.83%	-7.11%	8.61%	2.82%	-1.40%	-4.32%
Pre Tax Income Margin	-19.95%	-22.84%	-2.56%	-0.94%	-4.50%	-10.52%	8.33%	2.75%	-2.16%	-6.42%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-30.86	-36.05	-5.13	-1.33	-9.57	-23.23	31.24	11.17	-8.00	-24.50
NOPAT to Interest Expense	-21.98	-25.38	-2.89	-0.75	-6.65	-16.38	31.26	10.46	-5.82	-17.16
EBIT Less CapEx to Interest Expense	-32.43	-37.21	-6.33	-2.25	-10.63	-24.21	30.23	9.91	-9.30	-25.64
NOPAT Less CapEx to Interest Expense	-23.55	-26.55	-4.10	-1.66	-7.71	-17.36	30.26	9.20	-7.12	-18.29
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Oscar Health's Financials

When does Oscar Health's financial year end?

According to the most recent income statement we have on file, Oscar Health's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Oscar Health's net income changed over the last 5 years?

Oscar Health's net income appears to be on a downward trend, with a most recent value of $26.12 million in 2024, falling from -$261.18 million in 2019. The previous period was -$270.59 million in 2023.

What is Oscar Health's operating income?

Oscar Health's total operating income in 2024 was $57.27 million, based on the following breakdown:

Total Gross Profit: $9.18 billion
Total Operating Expenses: $9.12 billion

How has Oscar Health revenue changed over the last 5 years?

Over the last 5 years, Oscar Health's total revenue changed from $488.19 million in 2019 to $9.18 billion in 2024, a change of 1,779.9%.

How much debt does Oscar Health have?

Oscar Health's total liabilities were at $3.82 billion at the end of 2024, a 36.8% increase from 2023, and a 109.8% increase since 2020.

How much cash does Oscar Health have?

In the past 4 years, Oscar Health's cash and equivalents has ranged from $826.33 million in 2020 to $1.87 billion in 2023, and is currently $1.53 billion as of their latest financial filing in 2024.

How has Oscar Health's book value per share changed over the last 5 years?

Over the last 5 years, Oscar Health's book value per share changed from 0.00 in 2019 to 4.10 in 2024, a change of 409.9%.

Remove Ads

Related Companies

This page (NYSE:OSCR) was last updated on 4/16/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oscar Health (OSCR) Financials

Frequently Asked Questions About Oscar Health's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oscar Health (OSCR) Financials

Annual Income Statements for Oscar Health

Quarterly Income Statements for Oscar Health

Annual Cash Flow Statements for Oscar Health

Quarterly Cash Flow Statements for Oscar Health

Annual Balance Sheets for Oscar Health

Quarterly Balance Sheets for Oscar Health

Annual Metrics and Ratios for Oscar Health

Quarterly Metrics and Ratios for Oscar Health

Frequently Asked Questions About Oscar Health's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools